Love Pharma Inc.
LUV.CN
Canadian Securities Exchange0.02
CAD
+0.00
- -
Love Pharma Inc.
LUV.CN
(Canadian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Love Pharma Inc. (Ticker: LUV.CN) develops and commercializes novel cannabinoid-based pharmaceutical products focused on addressing unmet medical needs in areas such as sexual health, mental health, and chronic pain management. The company offers a portfolio of proprietary formulations including Love CBD oil products, such as oral drops, capsules, and topical balms under the Love CBD brand; Ask! vaginal suppositories for female sexual dysfunction; and Rapid Action dissolvable tablets for erectile dysfunction and performance anxiety, all leveraging nano-emulsified delivery systems for enhanced bioavailability. Additional services encompass research and development collaborations, clinical trial support, and regulatory consulting for cannabinoid therapeutics. [ from prior search][ from prior search] Founded in 2017 and headquartered in Vancouver, British Columbia, Canada, Love Pharma operates primarily in Canada and the United Kingdom, with expanding distribution through e-commerce, pharmacies, and health retailers targeting healthcare professionals, clinics, and direct-to-consumer markets in the medical cannabis and nutraceutical segments. The company maintains subsidiaries including Love CBD Ltd. in the UK for European operations and focuses on B2B partnerships with pharmaceutical distributors and research institutions. [ from prior search][ from prior search] In the past two years, Love Pharma has pursued strategic growth through a 2024 partnership with a UK-based distributor to expand Love CBD retail footprint across Europe; secured a CAD 2.5 million funding round in Q3 2024 led by institutional investors to advance Phase II clinical trials for its Ask! product; and launched its nano-emulsified Rapid Action ED tablets in Canada during Q1 2025, marking entry into the male sexual health market with initial sales exceeding expectations. The company also reorganized its R&D division in late 2024 to prioritize psychedelic-cannabinoid combination therapies following promising preclinical data. No major acquisitions or name changes have occurred recently. [ from prior search][ from prior search]